Anti-Influenza A Virus (H7N9) Neuraminidase [3C10-3] Antibody

This mouse IgG1 kappa monoclonal antibody was raised against beta-propiolactone (BPL)-inactivated and purified RG32a virus and recognizes influenza A virus (H7N9) neuraminidase.

Highlights:

  • Reacts with Influenza A Virus (H7N9) Neuraminidase
  • Suitable for ELISA, ELLA and MUNANA applications

Influenza A virus subtype H7N9 is a virus that normally infects avian populations but some variants have been known to occasionally infect humans This influenza contains protein on the surface neuraminidase (NA). The avian influenza A(H7N9) virus designation of H7N9 identifies it as having HA of the H7 subtype and NA of the N9 subtype. Symptoms include fever, cough, and shortness of breath, which may progress to severe pneumonia.

From a laboratory at Centers for Disease Control and Prevention.

Catalog Number Product Size AVAILABILITY Price Qty
ECD024-FP
Anti-Influenza A Virus (H7N9) Neuraminidase [3C10-3] Antibody
100ug 3-5 weeks
Regular Price:$299.00

This product is for sale to Nonprofit customers only. For profit customers, please Contact Us for more information.

Specifications

Product Type: Antibody
Antigen: Influenza A virus (H7N9) neuraminidase
Isotype: IgG1 kappa
Clonality: Monoclonal
Clone Name: 3C10-3
Immunogen: Beta-propiolactone (BPL)-inactivated and purified RG32a virus
Species Immunized: Mouse
Purification Method: Protein G
Buffer: 0.1M Sodium Phosphate, pH 7.4, 0.15M NaCl, 0.05% (w/v) Sodium Azide
Tested Applications: ELISA, ELLA, MUNANA
Storage: -20C
Shipped: Cold Packs

References
  1. Wilson JR, Guo Z, Reber A, Kamal RP, Music N, Gansebom S, Bai Y, Levine M, Carney P, Tzeng WP, Stevens J, York IA. An influenza A virus (H7N9) anti-neuraminidase monoclonal antibody with prophylactic and therapeutic activity in vivo. Antiviral Res. 2016 Nov;135:48-55. doi: 10.1016/j.antiviral.2016.10.001. Epub 2016 Oct 3.
  2. Wilson JR, Belser JA, DaSilva J, et al. An influenza A virus (H7N9) anti-neuraminidase monoclonal antibody protects mice from morbidity without interfering with the development of protective immunity to subsequent homologous challenge. Virology. 2017;511:214–221. doi:10.1016/j.virol.2017.08.016.

If you publish research with this product, please let us know so we can cite your paper.

Loading...